Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids + nigella sativa oil
- Development stage
- Unknown
- Lead developer
- TriNutra
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Omega-3 fatty acids + nigella sativa oil is a combination nutraceutical supplement investigated for its potential to modulate the immune response and improve clinical outcomes in patients with COVID-19. The combination consists of omega-3 fatty acids (EPA and DHA) and Nigella sativa oil, which is standardized to its primary bioactive component, thymoquinone. Thymoquinone is known for its anti-inflammatory, antiviral, and immunomodulatory properties, including the ability to reduce pro-inflammatory cytokines such as IL-2, IL-4, IL-6, and IL-12, while enhancing levels of interferon-gamma (IFN-γ) and immunoglobulins. This combination was evaluated in a Phase 2/3 clinical trial sponsored by Beni-Suef University as an adjunctive therapy to boost the human immune system against SARS-CoV-2 infection.
- Other names
- omega-3 + thymoquinoneomega-3 fatty acid + nigella sativa oilomega 3 + nigella sativa oil
02
Targets
IL12 (Interleukin-12)IL-2 (Interleukin 2)IL-4 (Interleukin 4)IL-6 (Interleukin 6)IFNG (Interferon gamma)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on omega-3 fatty acids + nigella sativa oil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3 fatty acids + nigella sativa oil.